APLS
Apellis Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$41.03
+0.00%Latest reported
- Last report date
- May 7, 2026
- EPS actual
- $0.15
- EPS estimate
- -$0.38
- Revenue actual
- $268.3M
- Revenue estimate
- $210.5M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 7
- EPS misses (12Q)
- 5
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +62.1%
- Revenue beats (12Q)
- 9
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| May 7, 2026 | -$0.38 | $0.15 | Beat 139.47% | $268.3M |
| Oct 30, 2025 | $1.03 | $1.67 | Beat 62.14% | $458.6M |
| Jul 31, 2025 | -$0.44 | -$0.33 | Beat 25.00% | $178.5M |
| Feb 28, 2025 | -$0.37 | -$0.29 | Beat 21.62% | $212.5M |
| Aug 1, 2024 | -$0.33 | -$0.28 | Beat 15.15% | $199.7M |
| Feb 27, 2024 | -$0.66 | -$0.73 | Miss -10.61% | $146.4M |
| Nov 1, 2023 | -$0.84 | -$1.17 | Miss -39.29% | $99.2M |
| May 4, 2023 | -$1.42 | -$1.56 | Miss -9.86% | $44.8M |
| Feb 21, 2023 | -$1.65 | -$1.50 | Beat 9.09% | $22.7M |
| May 4, 2022 | -$1.36 | -$1.42 | Miss -4.41% | $14.4M |
| Feb 28, 2022 | -$1.32 | -$1.61 | Miss -21.97% | $60.3M |
| Feb 25, 2021 | -$0.75 | $0.93 | Beat 224.00% | $250.0M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of May 7, 2026